Why BGPT?
logo

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what falsifiable science actually supports before you trust the answer.

Press Enter ↡ to search evidence


     Quick Analysis Plan



    The supplied evidence contains no fibroblast or keratinocyte conditional IL-17RA knockout data; no meta-analysis of skin cell-type specificity is possible from these records. The closest cell-type-specific evidence is B cell-intrinsic IL-17RA deletion reducing MHV68 GC B cell latency ~8-fold, plus global KO protection in cigarette smoke emphysema and macrophage/astrocyte signaling studies ().


     Long Analysis Plan



    Evidence Gap

    The requested meta-analysis cannot be performed: none of the supplied records contain fibroblast or keratinocyte conditional IL-17RA KO data. Cell-type-specific IL-17RA evidence here is limited to B cells (8-fold reduction in latently infected GC B cells with B cell-intrinsic deletion) (), with complementary non-skin evidence from global IL-17RA KO emphysema protection (), macrophage IL-17RA-TRAF6-JNK signaling (), and astrocyte IL-17RA/ACT1/NF-kB signaling (). Missing: skin fibroblast/keratinocyte floxed-IL17RA mouse data, psoriasis-relevant conditional KO effect sizes, and cell-type-resolved expression datasets. Confidence: high that the gap is real; low on any skin-cell conclusion.



    Feedback:    

    Updated: November 17, 2026



     Top Data Sources ExportMCP



     Hypothesis Graveyard



    Assuming IL-17RA action is uniform across resident skin cells: falsified by analogyβ€”B cell-intrinsic KO produced phenotype-specific latency effects (8-fold GC reduction) without altering antibody titers, showing IL-17RA roles are cell-type-restricted rather than uniform.

     Science Art


    Meta-analysis: IL-17RA cell-type specificity fibroblast vs keratinocyte conditional KO evidence Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($64 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT